Drug intelligence / Profile preview

OT-TBU

Development stage: Preclinical
Lead developer: Pangea Bio
Modality: Small Molecules

Overview

OT-TBU is a preclinical-stage small molecule developed by Pangea Bio that targets the Tropomyosin receptor kinase B (TrkB) receptor. The drug is being developed for the treatment of depression and neurodevelopmental disorders. TrkB is a key mediator of neuronal plasticity and survival, serving as the high-affinity catalytic receptor for brain-derived neurotrophic factor (BDNF). By targeting this receptor, OT-TBU aims to address the neurobiological deficits associated with mood disorders and developmental conditions of the central nervous system.

Targets

NTRK2 (Tropomyosin-related kinase receptor type B)

Beyond the preview

Go deeper on OT-TBU.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OT-TBU.

Explore the full profile